Biomedical research, neglected diseases, and well-ordered science

Theoria-Revista De Teoria Historia Y Fundamentos De La Ciencia

Volumn 24, Issue 3, 2009, Pages 263-282

  Reiss, Julian ^a   Kitcher, Philip ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Howard Hughes Medical Institute   (United States)

Author keywords

Biomedical research; Neglected diseases; Well ordered science

Indexed keywords

EID: 77955177905     PISSN: 04954548     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Chin, T., 2002. Drug Firms Score by Paying Doctors for Time', American Medical News. May 6. downloadable at: http://www.amednews.com [Accesed on August 1st, 2009]
2. Cohen, J. and Gürtler, R., 2001. Modeling Household Transmission of American Trypanosomiasis. Science 293, pp. 694-8.
3. DiMasi, J., Hansen, R. and Grabowski, H., 2003. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22, pp. 151-85.
4. Engels, D. and Savioli, L., 2006. Reconsidering the Underestimated Burden Caused by Neglected Tropical Diseases. Trends in Parasitology 22 (8), pp. 363-6.
5. Families USA, 2002. Profiting from Pain: Where Prescription Drugs Dollars Go. Publication 02-105. Washington (DC): Families USA Foundation.
6. Flory, J. and Kitcher, P., 2004. Global Health and the Scientific Research Agenda. Philosophy and Public Affairs 32 (1), pp. 36-65.
7. Global Forum for Health Research, 2004. The 10/90 Report on Health Research 2003-2004. Geneva: Global Forum for Health Research.
8. Global Forum for Health Research, 2006. Monitoring Financial Flows for Health Research 2006: The Changing Landscape of Health Research for Development, Geneva: Global Forum for Health Research.
9. Goozner, M., 2004. The $800 Million Pill: The Truth behind the Cost of New Drugs. Berkeley (CA): University of California Press.
10. Hartman, M., Martin, A., McDonnell, P., Catlin, A. and the National Health Expenditure Accounts Team, 2009. National Health Spending In 2007: Slower Drug Spending Contributes To Lowest Rate Of Overall Growth Since 1998. Health Affairs 28 (1), pp. 246-61
11. Hensley, S., 2003. Follow the Money: Drug Prices at Faster Clip, Placing Burden on Consumers. Wall Street Journal, April 15.
12. Kahana, N. and Katz, E., 1990. Monopoly, Price Discrimination, and Rent-Seeking. Journal of Public Choice 64 (1), pp. 93-100.
13. Kassirer, J., 2005. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. New York (NY): Oxford University Press.
14. Kirkwood, J., 2003. What's in a Name? The Eagle-Tribune, September 1.
15. Kitcher, P., 2001. Science, Truth and Democracy. Oxford: OUP.
16. Kreling, D., Mott, D., Wiederholt, J., Lundy, J., and Levitt, L., 2001. Prescription Drug Trends: A Chartbook Update. Menlo Park (CA): The Kaiser Family Foundation.
17. Lexchin, J. and Light, D., 2006. Commercial Influence and the Content of Medical Journals. British Medical Journal 332 (7555), p. 1444.
18. Mitchell, S., 2009. Unsimple Truths: Science, Complexity, and Policy. Chicago (IL): University of Chicago Press.
19. Moynihan, R. and Cassels, A., 2005. Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients. New York: Nation.
20. Murray, C. and Acharya, A., 1997. Understanding DALYs. Journal of Health Economics 16, pp. 703-30
21. Neukirchen, H., 2006, Der Pharma-Report. Munich: Droemer Knaur.
22. Pharmaceutical R&D Policy Project, 2005. The New Landscape of Neglected Disease Drug Development, London: The London School of Economics and Political Science.
23. Pogge, T., 2005. Human Rights and Global Health: A Research Program. Metaphilosophy 36 (1/2), pp. 182-209
24. Public Citizen (2001). Rx R&D Myths: The Case Against the Drug Industry's R&D "Scare Card". Washington (DC): Public Citizen Congress Watch.
25. Public Citizen, 2003a. 2002 Drug Industry Profits: Hefty Pharmaceutical Company Margins Dwarf Other Industries. Washington (DC): Public Citizen Congress Watch.
26. Public Citizen, 2003b. The Other Drug War 2003: Drug Companies Deploy an Army of 675 Lobbyists to Protect Profits. Washington (DC): Public Citizen Congress Watch.
27. Rosenthal, M., Bernt, E., Donohue, J., Frank, R. and Epstein, A., 2002. Promotion of Prescription Drugs to Consumers. New England Journal of Medicine 346 (7), pp. 498-505.
28. Sachs, J., 2005. The End of Poverty. New York (NY): Penguin.
29. Smith, R. 2003. Medical Journals and Pharmaceutical Companies: Uneasy Bedfellows. British Medical Journal 326 (7400), p. 1202.
30. Truiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R. and Ford, N., 2002. Drug Development for Neglected Diseases: A Deficient Market and a Public-Health Policy Failure. The Lancet 359, pp. 2188-94.
31. Vanderelst, D. and Speybroek, N., 2010. Quantifying the Lack of Scientific Interest in Neglected Tropical Diseases. PLoS Neglected Tropical Diseases 4 (1), e576. doi:10.1371/journal.pntd.0000576
32. Wilkes, M., Bell, R. and Kravitz, R., 2000. Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and Implications. Health Affairs 19 (2), pp. 110-128
33. World Health Organization, 2004. Changing History: The World Health Report 2004. Geneva: The World Health Organization.